Crossmark

Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance)

Crossref DOI link: https://doi.org/10.1007/s11523-016-0467-0

Published Online: 2016-12-09

Published Print: 2017-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hubbard, Joleen M.

Mahoney, Michelle R.

Loui, William S.

Roberts, Lewis R.

Smyrk, Thomas C.

Gatalica, Zoran

Borad, Mitesh

Kumar, Shaji

Alberts, Steven R.
Funding

Funding for this research was provided by:

Foundation for the National Institutes of Health (U10CA180821 & U10CA180882)

National Cancer Institute (CA25224)

Bayer Pharmaceuticals (REACH Program)
License Information

Text and Data Mining valid from 2016-12-09

Version of Record valid from 2016-12-09
More Information

Article History

First Online: 9 December 2016

Compliance with Ethical Standards

:

: Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Numbers U10CA180821 and U10CA180882 to the Alliance for Clinical Trials in Oncology (Alliance) and the following funding to the legacy North Central Cancer Treatment Group (NCCTG): NCI Grant CA25224 and Bayer Pharmaceuticals and Bayer’s REACH Program.The following institutions participated in this study:Geisinger Clinic & Medical Center CCOP, Danville, PA 17822 (Christian S. Adonizio, M.D.) -Grant #CA-35448Grand Rapids Clinical Oncology Program, Grand Rapids, MI 49503 (Gilbert D.A. Padula, M.D.)Mayo Clinic Arizona, Scottsdale, AZ 85259-5404 (William W. Wong, M.D.)Mayo Clinic Rochester, Rochester, MN 55905 (Steven R. Alberts, M.D.)Metro-Minnesota Community Clinical Oncology Program, St. Louis Park, MN 55416 (David M. Anderson) – Grant #CA-35267Michigan Cancer Research Consortium, Ann Arbor, MI 48106 (Philip J. Stella, M.D.) - Grant #CA-63848Montana Cancer Consortium, Billings, MT 59101 (Benjamin T. Marchello, M.D.)Rapid City Regional Oncology Group, Rapid City, SD 59709 (Mark T. Schroeder, M.D.)St. Vincent Regional Cancer Center CCOP, Green Bay, WI 54303 (Anthony J. Jaslowski, M.D.)Wichita Community Clinical Oncology Program, Wichita, KS 67214-3882 (Shaker R. Dakhil, M.D.) - Grant #CA-35431

: The authors declare no conflict of interest.The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Free to read: This content has been made available to all.

Document is current

Any future updates will be listed below